Compare · AMGN vs BHSE
AMGN vs BHSE
Side-by-side comparison of Amgen Inc. (AMGN) and Bull Horn Holdings Corp. (BHSE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and BHSE operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $185.95B, about 1981.5x BHSE ($93.8M).
- AMGN has hit the wire 9 times in the past 4 weeks while BHSE has been quiet.
- AMGN has more recent analyst coverage (25 ratings vs 0 for BHSE).
- Company
- Amgen Inc.
- Bull Horn Holdings Corp.
- Price
- $344.50-1.18%
- $12.50+50.42%
- Market cap
- $185.95B
- $93.8M
- 1M return
- -2.63%
- -
- 1Y return
- +21.63%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2020
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 0
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Bull Horn Holdings Corp.
Bull Horn Holdings Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the sports, entertainment, and brands sectors. The company was incorporated in 2018 and is based in Miami Beach, Florida.
Latest AMGN
- AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS
- Amgen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
- SEC Form DEFA14A filed by Amgen Inc.
- Canaccord Genuity initiated coverage on Amgen with a new price target
- SEC Form DEFA14A filed by Amgen Inc.
- SEC Form DEFA14A filed by Amgen Inc.
- SEC Form DEF 14A filed by Amgen Inc.
- AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
- Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
Latest BHSE
- SEC Form SC 13G filed by Bull Horn Holdings Corp.
- SEC Form 424B3 filed by Bull Horn Holdings Corp.
- SEC Form 424B3 filed by Bull Horn Holdings Corp.
- Bull Horn Holdings Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events
- Cogley Brian bought $3,350 worth of shares (5,000 units at $0.67), increasing direct ownership by 20% to 30,000 units (SEC Form 4)
- New insider Cogley Brian claimed ownership of 30,000 shares (SEC Form 3)
- Desilva Tara bought $1,305 worth of shares (2,266 units at $0.58), increasing direct ownership by 8% to 32,266 units (SEC Form 4)
- Yerace Daniel Alexander bought $7,486 worth of shares (10,850 units at $0.69), increasing direct ownership by 1% to 1,071,455 units (SEC Form 4)
- Salkind Gene bought $8,004 worth of shares (11,600 units at $0.69), increasing direct ownership by 4% to 284,056 units (SEC Form 4)
- Mehalick David bought $16,747 worth of shares (25,054 units at $0.67), increasing direct ownership by 0.91% to 2,782,615 units (SEC Form 4)